ImaginAb Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
ImaginAb is a clinical-stage global biotechnology company focused on developing imaging agents and radiopharmaceutical therapies, built on minibody and cys-diabody platforms. Its lead candidate, 89Zr crefmirlimab berdoxam, known as CD8 ImmunoPET, is in Phase II and has been licensed by multiple pharmaceutical and biotech firms for use in imaging within immunotherapy trials, primarily in oncology. The company serves pharmaceutical and biotech customers seeking new imaging tools to support cancer immunotherapy programs. Based in Inglewood, California, the company operates within the biotechnology research sector with a focus on diagnostics and radiopharmaceuticals for cancer. In January 2025, Telix Pharmaceuticals Limited completed the acquisition of ImaginAb, a move that aligns with continued development of ImaginAb's lead imaging asset, CD8 ImmunoPET, which is in Phase II trials.